Switching from insulin to dulaglutide therapy in patients with type 2 diabetes: A real-world data study.

Jiwoo LeeHwi Seung KimChang Hee JungJoong-Yeol ParkWoo Je Lee

Published in: Diabetes/metabolism research and reviews (2021)

Switching from insulin to dulaglutide can lead to significant improvement in HbA1c levels and body weight reduction in T2DM patients over 6 months. Higher baseline HbA1c is associated with a better clinical response to dulaglutide.

Keyphrases

body weight
type diabetes
end stage renal disease
glycemic control
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
electronic health record
big data
metabolic syndrome
stem cells
machine learning
mesenchymal stem cells
insulin resistance
weight loss
data analysis